How effective is stem cell therapy for Degenerative Disc Disease?
Clinical research on stem cell therapy for degenerative disc disease (DDD) shows encouraging but mixed results.

A 2026 systematic review and meta-analysis of seven randomized trials with 594 patients found that intradiscal injection of mesenchymal stem cells (MSCs) was associated with greater reductions in pain and disability than control treatments, with benefits that became more evident between 12 and 36 months. However, the RESPINE trial, a large European randomized placebo-controlled study, found no significant difference between MSCs and a sham procedure at 12 months, partly because many patients in the placebo group also improved. Safety has been reassuring in these trials. At Stem Cell Mexico, spine protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, with image guidance and rehabilitation, and results vary between individuals.
This guide explains how effectiveness is measured for back pain, what the studies found, why placebo responses are so important in spine research and which factors seem to influence results.
How effectiveness is measured in back pain studies
Back pain is subjective and fluctuates from day to day, so researchers use standardized tools:
- Pain scales: the Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS), from 0 (no pain) to 10 or 100 (worst pain).
- Disability scores: the Oswestry Disability Index (ODI), which measures how pain affects walking, sitting, sleeping, lifting, social life and work.
- Responder rates: the percentage of patients who reach a defined improvement, such as at least 20% or 30% less pain.
- Minimal clinically important difference (MCID): the smallest change patients perceive as meaningful. A result can be statistically significant but smaller than the MCID.
- Imaging: MRI changes in disc hydration or height, which do not always correlate with pain.
- Use of pain medication and return to work or activity.
When evaluating any claim of effectiveness, it helps to ask which of these measures improved, by how much and compared with what.
What the evidence shows
Meta-analysis: Asian Spine Journal, 2026
- Data: seven randomized controlled trials, 594 patients with chronic low back pain from DDD.
- Findings: intradiscal MSCs were associated with significantly greater pain reduction than control, with benefits more evident at 12 to 36 months, and improvements in ODI disability scores.
- Safety: adverse events, serious complications and discontinuations were similar between groups.
RESPINE trial: Annals of the Rheumatic Diseases, 2024
- Participants: 114 patients with chronic low back pain related to disc degeneration, in several European centers.
- Treatment: a single intradiscal injection of 20 million allogeneic bone-marrow-derived MSCs, compared with a sham procedure.
- Primary result: at 12 months, 74% of the MSC group and 69% of the placebo group met the responder definition, a difference that was not statistically significant.
- Safety: no serious treatment-related adverse events.
- Interpretation: the trial confirmed safety and showed how much back pain can improve with a structured program, attention and time.
Why results differ between studies
- Cell type and source: bone marrow, adipose, umbilical cord and other products have been tested, at different doses.
- Patient selection: some trials included only patients with mild to moderate degeneration at one level; others were broader.
- Control groups: sham procedures, saline injections, hyaluronic acid or conservative care produce different comparison effects.
- Follow-up length: some benefits appear only after 12 months, so short trials may miss them.
- Outcome definitions: responder thresholds vary.
The placebo effect in back pain
Back pain is one of the conditions with the strongest placebo responses in medicine. Expectations, attention from clinicians, the experience of a procedure, natural fluctuations and regression to the mean (pain often improves after a bad period, whatever is done) all contribute. In RESPINE, more than two-thirds of patients in the sham group improved meaningfully. It is also why testimonials are not a reliable measure of effectiveness.
Factors that seem to influence results
- Source of pain: patients whose pain is primarily discogenic, confirmed by careful evaluation, are more likely to benefit from disc-targeted treatment than those whose pain comes from facet joints, sacroiliac joints, muscles or nerves.
- Degree of degeneration: discs that retain some height and hydration may respond better than severely collapsed discs.
- Number of levels: single-level disease is more often studied than multi-level degeneration.
- Rehabilitation and conditioning: core strength, flexibility, weight management and activity level influence outcomes.
- Psychological factors: sleep, stress, mood and fear of movement affect how pain is experienced.
- Duration of pain: long-standing pain may involve changes in pain processing in the nervous system that local treatments do not address.
A realistic timeline
- First days: temporary increase in back pain after injection is common.
- Weeks 2 to 12: gradual return to activity and rehabilitation; some patients notice changes, others do not.
- Months 3 to 12: the period when most trials assess primary outcomes.
- Beyond 12 months: some studies report benefits that become more evident over time.
Because of this timeline, judging results in the first weeks is not reliable. Keeping a simple diary of pain scores, sleep and activities during the first year helps you and your doctor see trends that are easy to miss from one visit to the next.
What a meaningful improvement looks like
For an individual patient, effectiveness is best judged against personal goals rather than averages. Examples of meaningful change include:
- Being able to sit through a work meeting, a car trip or a meal without needing to stand up.
- Walking longer distances or returning to a sport or hobby.
- Sleeping through the night more often.
- Needing fewer pain medications.
- A drop of about two points or more on a 0 to 10 pain scale, or a clear reduction in ODI score.
Setting two or three specific goals before treatment, and writing them down, makes it much easier to judge later whether treatment helped.
Warning signs when comparing clinics
Be cautious if a clinic:
- Uses satisfaction rates or testimonials instead of measured outcomes.
- Promises to regenerate discs or guarantees that you will avoid surgery.
- Does not explain the difference between disc pain and other sources of back pain.
- Performs spine injections without image guidance.
- Says the treatment is risk-free.
How Stem Cell Mexico measures results
- Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells or other cell sources are used.
- Laboratory: produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
- Baseline: pain scores, ODI, medication use and functional goals are recorded before treatment, along with your MRI.
- Follow-up: the same measures are repeated at about 3, 6 and 12 months.
- Outcome tracking: results are followed with pain scores, ODI, medication use and specific functional goals rather than reduced to one clinic-wide success percentage. This makes it easier to judge whether the treatment produced a meaningful change for the individual patient.
How cell therapy fits into an active recovery plan
Regenerative treatment is most useful when it is integrated with a plan that also addresses strength, mobility, mechanics and the behaviors that influence disc loading. Exercise-based rehabilitation remains valuable because it helps the patient turn pain reduction or improved tolerance into better real-world function.
Clinical guidelines for low back pain emphasize staying active, exercise and appropriate conservative care. MSC therapy is a newer regenerative option and is evaluated for selected patients whose imaging, symptoms and treatment history suggest a disc-related pain source. At Stem Cell Mexico, the goal is not to replace movement or rehabilitation, but to combine precise image-guided treatment with a recovery plan that gives the patient the best opportunity to use any biological improvement.
Safety in brief
In randomized trials, intradiscal MSC injections had safety profiles similar to control procedures. Possible risks include a temporary increase in pain and, rarely, disc infection, bleeding or nerve irritation. No treatment is free of risk, which is why the procedure is performed with sterile technique and image guidance and followed by clear instructions on activity and warning signs.
What our patients usually receive
Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:
- 20 to 40 million Wharton's jelly MSCs per treated area, applied by direct injection with ultrasound guidance, or fluoroscopy guidance for the spine.
- Platelet-rich plasma (PRP) in many plans, applied together with the cells.
- One night at our facilities with nursing and medical monitoring.
- Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
- Your recent imaging: an MRI of the area no older than three months is requested; if yours is older, a new one can be scheduled in Tijuana on your arrival day.
Based on what patients tell us, many begin to notice improvement within a few days to a few weeks after the application, while others improve more gradually over the following months. Our team stays in contact after treatment to follow your progress and decide whether a second application or a PRP session could help.
Questions to ask during your evaluation
- How confident are you that my pain comes from the disc?
- Which measures will we use to judge results, and when?
- What results are realistic, including the possibility of no change?
- How does the evidence apply to my level and degree of degeneration?
- What rehabilitation program should I follow?
Bottom line
Randomized evidence in degenerative disc disease is still developing, but a 2026 meta-analysis found encouraging improvements in pain and function and clinical trials have shown a reassuring safety profile. At Stem Cell Mexico, Wharton's jelly MSCs are delivered with image guidance and paired with rehabilitation and objective follow-up. A medical evaluation helps determine whether your pain pattern, MRI findings and goals match the patients most likely to benefit from this regenerative approach.
References
- Rahyussalim et al. Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials. Asian Spine Journal, 2026 (opens in a new tab)
- RESPINE consortium. Allogenic bone marrow-derived mesenchymal stromal cell-based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study). Annals of the Rheumatic Diseases, 2024 (opens in a new tab)
- NICE guideline NG59: Low back pain and sciatica in over 16s, assessment and management (opens in a new tab)
- International Society for Stem Cell Research (ISSCR): The ISSCR Guide to Stem Cell Treatments (opens in a new tab)
